Share on StockTwits

GlaxoSmithKline plc (NYSE:GSK) saw some unusual options trading activity on Wednesday. Stock traders bought 3,301 put options on the company, Analyst Ratings News reports. This represents an increase of 404% compared to the typical volume of 655 put options.

A number of research firms have recently commented on GSK. Analysts at Deutsche Bank reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Tuesday. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline plc in a research note on Wednesday, May 21st. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $53.50.

Shares of GlaxoSmithKline plc (NYSE:GSK) traded down 0.24% during mid-day trading on Wednesday, hitting $53.09. 2,383,402 shares of the company’s stock traded hands. GlaxoSmithKline plc has a 52-week low of $48.30 and a 52-week high of $56.73. The stock’s 50-day moving average is $54.77 and its 200-day moving average is $53.73. The company has a market cap of $127.8 billion and a price-to-earnings ratio of 15.21.

GlaxoSmithKline plc (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.70 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.72 by $0.02. Analysts expect that GlaxoSmithKline plc will post $3.44 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Thursday, July 10th. Stockholders of record on Friday, May 16th will be paid a dividend of $0.64 per share. This represents a $2.56 annualized dividend and a dividend yield of 4.82%. The ex-dividend date is Wednesday, May 14th.

GlaxoSmithKline plc (NYSE:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.